Actuate 1901: 9-ING-41 in Myelofibrosis

Part of paid clinical trials in Los Angeles, California.

Sponsor
Actuate Therapeutics Inc.
Study ID
NCT04218071
Phase
PHASE2
Status
Completed

Conditions

  • Myelofibrosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ruxolitinib — DRUG
    Ruxolitinib at protocol-specified doses for given platelet count
  • 9-ING-41 — DRUG
    9-

Study Details

9-ING-41 has anti-cancer clinical activity while not causing myelosuppression, and has both pre-clinical anti-fibrotic activity and activity against myelofibrosis. This Phase 2 study will study its efficacy in patients with advanced myelofibrosis.

Key Dates

Start date
Aug 20, 2020
Status verified
Feb 2024
Primary completion
Oct 13, 2022
Completion
Jan 18, 2024

Study Design

Enrollment
17 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: 9-ING-41
    9-ING-41 is administered by intravenous infusion twice weekly at a dose of 9.3 mg/kg. Cycle duration is 28 days.
  • Experimental: 9-ING-41 plus Ruxolitinib
    9-ING-41 9.3 mg/kg will be administered by intravenous infusion twice weekly for cycle durations of 28 days with Ruxolitinib at doses specified in the protocol as appropriate for patient's platelet count.

Primary Outcome Measure

Response rate [ Time Frame: 3-24 months ]

Locations (9)

FacilityCityStateZIPSite coordinators
University of California Los AngelesLos AngelesCalifornia90095-
University of Southern CaliforniaLos AngelesCalifornia90033-
Georgia Cancer CenterAugustaGeorgia30912-
Mayo ClinicRochesterMinnesota55905-
Siteman Cancer CenterSt LouisMissouri63100-
Weill Cornell Medicine | NewYork-Presbyterian Meyer Cancer CenterNew YorkNew York10065-
Duke Cancer CenterDurhamNorth Carolina27710-
Brown UniversityProvidenceRhode Island02912-
Fred Hutchinson Cancer Research CenterSeattleWashington98109-

Find similar trials in Los Angeles, CA

By research site
University of California Los Angeles· Los Angeles, CAUniversity of Southern California· Los Angeles, CAGeorgia Cancer Center· Augusta, GAMayo Clinic· Rochester, MNSiteman Cancer Center· St Louis, MOWeill Cornell Medicine | NewYork-Presbyterian Meyer Cancer Center· New York, NY

Related Studies